Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. We were the first player in the market to commercialize all parts of an integrated diabetes management system.
In the company’s own words · 10-K filed Jun 29, 2026 · SEC EDGAR
Business segments
Q1 2026 · $790.0MThe company’s own SEC segment disclosure.
- Continuous Glucose Monitoring Systems CGM$390.0M49%
- Consumables$244.0M31%
- Pumps$151.0M19%
- Product And Service Other$5.0M1%
MiniMed Group, Inc. (MMED) reported revenue of $837M in Q4 2026 (quarter ended April 24, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $185M. For the full year FY2026, revenue was $3.10B (+14% year on year) and net income −$333M. Its largest product in 2026-Q1 was Continuous Glucose Monitoring Systems CGM at $390M, 49% of the disclosed total, just ahead of Consumables at 31%.
Raw charts
6 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
The closest names by size in the same industry